Journal of the American Society of Nephrology

Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.  33:908-917. 2022

A Comprehensive Immune Cell Atlas of Cystic Kidney Disease Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice.  33:747-768. 2022

Lipopolysaccharide Pretreatment Prevents Medullary Vascular Congestion following Renal Ischemia by Limiting Early Reperfusion of the Medullary Circulation.  33:769-785. 2022

The Non-Inferiority Complex: What Do Non-Inferiority Trials Tell Us?.  33:674-676. 2022

Alpha Globin Gene Copy Number Is Associated with Prevalent Chronic Kidney Disease and Incident End-Stage Kidney Disease among Black Americans.  33:213-224. 2022

Sex-dependent effects of nephron ift88 disruption on bp, renal function, and cystogenesis.  32:2210-2222. 2021

Could NAD¹ precursor supplements induce a legacy of protection against diabetic nephropathy?.  32:1270-1273. 2021

In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes.  32:695-706. 2021

AKI treated with renal replacement therapy in critically ill patients with COVID-19.  32:161-176. 2021

Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) study.  32:115-126. 2021

Prognostic significance of ambulatory BP monitoring in CKD: A report from the chronic renal insufficiency cohort (cric) study.  31:2609-2621. 2020

Authors’ Reply.  31:2228-2229. 2020

Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial.  31:2122-2132. 2020

Early predictors of arteriovenous fistula maturation: A novel perspective on an enduring problem.  31:1617-1627. 2020

Exocyst Genes Are Essential for Recycling Membrane Proteins and Maintaining Slit Diaphragm in Drosophila Nephrocytes..  31:1024-1034. 2020

Clinical pig kidney xenotransplantation: How close are we?.  31:12-21. 2020

Bif-1 interacts with prohibitin-2 to regulate mitochondrial inner membrane during cell stress and apoptosis.  30:1174-1191. 2019

Exostosin 1/exostosin 2–associated membranous nephropathy.  30:1123-1136. 2019

Single-cell RNA sequencing identifies candidate renal resident macrophage gene expression signatures across species.  30:767-781. 2019

APOL1 kidney risk variants and cardiovascular disease: An individual participant data meta-analysis.  30:2027-2036. 2019

Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1.  30:2017-2026. 2019

Long-term outcomes of arteriovenous fistulas with unassisted versus assisted maturation: A retrospective national hemodialysis cohort study.  30:2209-2218. 2019

Tissue-resident macrophages promote renal cystic disease.  30:1841-1856. 2019

Erratum: Prediction of arteriovenous fistula clinical maturation from postoperative ultrasound measurements: Findings from the hemodialysis fistula maturation study (Journal of the American Society of Nephrology (2018) 29 (2735-2744)DOI:10.1681/ASN.2017111225).  31:665. 2018

Prediction of arteriovenous fistula clinical maturation from postoperative ultrasound measurements: Findings from the Hemodialysis Fistula Maturation Study.  29:2735-2744. 2018

A practical guide for treatment of rapidly progressive ADPKD with tolvaptan.  29:2458-2470. 2018

A novel method for rapid bedside measurement of GFR.  29:1609-1613. 2018

Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria.  29:1615-1623. 2018

Evaluation of potential living kidney donors in the APOL1 era.  29:1079-1081. 2018

Fibrotic venous remodeling and nonmaturation of arteriovenous fistulas.  29:1030-1040. 2018

Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.  29:620-635. 2018

Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery.  29:260-267. 2018

New ultrasound techniques promise further advances in AKI and CKD.  28:3452-3460. 2017

The clinical and economic effect of vascular access selection in patients initiating hemodialysis with a catheter.  28:3679-3687. 2017

Haploinsufficiency of the Transcription Factor Ets-1 Is renoprotective in dahl salt-sensitive rats.  28:3239-3250. 2017

Histopathology of veins obtained at hemodialysis arteriovenous fistula creation surgery.  28:3076-3088. 2017

Intimal hyperplasia, stenosis, and arteriovenous fistula maturation failure in the hemodialysis fistula maturation study.  28:3005-3013. 2017

Effects of intensive BP control in CKD.  28:2812-2823. 2017

Quantifying postdonation risk of ESRD in living kidney donors.  28:2749-2755. 2017

Long-term endothelin-a receptor antagonism provides robust renal protection in humanized sickle cell disease mice.  28:2443-2458. 2017

Cell-Free DNA and active rejection in kidney allografts.  28:2221-2232. 2017

Global cardiovascular and renal outcomes of reduced GFR.  28:2167-2179. 2017

Sickle cell trait and the risk of ESRD in blacks.  28:2180-2187. 2017

Association between soluble klotho and change in kidney function: The health aging and body composition study.  28:1859-1866. 2017

Prognostic value of serum biomarkers of autoimmunity for recurrence of IGA nephropathy after kidney transplantation.  28:1943-1950. 2017

Novel paradigms of salt and hypertension.  28:1362-1369. 2017

A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction.  28:1306-1313. 2017

APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death..  28:1106-1116. 2017

Polyomavirus reactivation and immune responses to kidney-specific self-antigens in transplantation.  28:1314-1325. 2017

SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function.  28:981-994. 2017

An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria.  28:494-503. 2017

BP control and long-term risk of ESRD and mortality.  28:671-677. 2017

Association between preoperative vascular function and postoperative arteriovenous fistula development.  27:3788-3795. 2016

Cellular and molecular mechanisms of AKI.  27:1288-1299. 2016

Sulfenic acid modification of endothelin b receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia.  27:398-404. 2016

Heme oxygenase-1 gene polymorphisms-toward precision medicine for AKI.  27:3229-3231. 2016

Macula densa nitric oxide synthase 1b protects against salt-sensitive hypertension.  27:2346-2356. 2016

Past decline versus current EGFR and subsequent mortality risk.  27:2456-2466. 2016

Predicted mutation strength of nontruncating PKD1 mutations AIDS genotype-phenotype correlations in autosomal dominant polycystic kidney disease.  27:2872-2884. 2016

Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathy.  27:3278-3284. 2016

Moving beyond minimization trials in kidney transplantation.  26:2898-2901. 2015

Outcomes of elderly patients after predialysis vascular access creation.  26:3133-3140. 2015

Phenotype-Genotype correlations and estimated carrier frequencies of primary hyperoxaluria.  26:2559-2570. 2015

A national study of outcomes among HIV-infected kidney transplant recipients.  26:2222-2229. 2015

Heme oxygenase-1 regulates myeloid cell trafficking in AKI.  26:2139-2151. 2015

The furosemide stress test and predicting AKI outcomes.  26:1762-1764. 2015

Current understanding of the role of complement in IgA nephropathy.  26:1503-1512. 2015

Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.  26:1290-1302. 2015

Contrasting cholesterol management guidelines for adults with CKD.  26:1173-1180. 2015

Lack of association of the APOL1 G3 haplotype in African Americans with ESRD.  26:1021-1025. 2015

Reassessing medical risk in living kidney donors.  26:1017-1019. 2015

Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy.  26:1195-1204. 2015

Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials.  26:160-172. 2015

Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.  26:133-147. 2015

Through a glass darkly: Seeking clarity in preventing late kidney transplant failure.  26:20-29. 2015

Lupus nephritis susceptibility loci in women with systemic lupus erythematosus.  25:2859-2870. 2014

Patient- And Provider-Reported Information about Transplantation and Subsequent Waitlisting.  25:2871-2877. 2014

CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.  25:1760-1773. 2014

Cytomegalovirus and anemia: Not just for transplant anymore.  25:1613-1615. 2014

Quality of life and outcomes in African Americans with CKD.  25:1849-1855. 2014

Sphingosine-1-phosphate evokes unique segment-specific vasoconstriction of the renal microvasculature.  25:1774-1785. 2014

Characterization of renal toxicity in mice administered the marine biotoxin domoic acid.  25:1187-1197. 2014

Fabry disease: Dose matters.  25:653-655. 2014

A within-patient analysis for time-varying risk factors of CKD progression.  25:606-613. 2014

The transcription factor E26 transformation-specific sequence-1 mediates neointima formation in arteriovenous fistula.  25:475-487. 2014

ABIN1 dysfunction as a genetic basis for lupus nephritis.  24:1743-1754. 2013

Cardiovascular risk factors in CKD associate with both ESRD and mortality.  24:1159-1165. 2013

Imatinib: Novel treatment of immune-mediated kidney injury.  24:694-701. 2013

Proximal tubule proliferation is insufficient to induce rapid cyst formation after cilia disruption.  24:456-464. 2013

Evidence-based cardiology in hemodialysis patients.  24:1934-1943. 2013

Mechanisms of light chain injury along the tubular nephron.  23:1777-1781. 2012

Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.  23:1579-1587. 2012

Development of a model of early-onset IgA nephropathy.  23:1364-1374. 2012

Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement.  23:1161-1171. 2012

Kidney function can improve in patients with hypertensive CKD.  23:706-713. 2012

Induction of IgA deposits and glomerulonephritis by IgA rheumatoid factor.  23:371-373. 2012

ETA activation mediates angiotensin II-induced infiltration of renal cortical T cells.  22:2187-2192. 2011

APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.  22:1991-1996. 2011

The pathophysiology of IgA nephropathy.  22:1795-1803. 2011

Albuminuria and racial disparities in the risk for ESRD.  22:1721-1728. 2011

Sepsis and acute kidney injury.  22:999-1006. 2011

Loss of primary cilia upregulates renal hypertrophic signaling and promotes cystogenesis.  22:839-848. 2011

Use of aspirin associates with longer primary patency of hemodialysis grafts.  22:773-781. 2011

Medicare reimbursement policies and hemodialysis vascular access outcomes: A need for change.  22:426-430. 2011

Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation.  22:579-585. 2011

Low socioeconomic status associates with higher serum phosphate irrespective of race.  21:1953-1960. 2010

Immunoglobulin light chains activate tubular epithelial cells through redox signaling.  21:1165-1173. 2010

Heme oxygenase-1 inhibits renal tubular macroautophagy in acute kidney injury.  21:1702-1712. 2010

Normal ciliogenesis requires synergy between the cystic kidney disease genes MKS-3 and NPHP-4.  21:782-793. 2010

Conditional mutation of Pkd2 causes cystogenesis and upregulates beta-catenin..  20:2556-2569. 2009

Cystin localizes to primary cilia via membrane microdomains and a targeting motif.  20:2570-2580. 2009

TβRI independently activates Smad- and CD2AP-dependent pathways in podocytes.  20:2127-2137. 2009

Ferritin prevents calcification and osteoblastic differentiation of vascular smooth muscle cells.  20:1254-1263. 2009

Plasma gelsolin and circulating actin correlate with hemodialysis mortality.  20:1140-1148. 2009

Kidney function influences warfarin responsiveness and hemorrhagic Complications.  20:912-921. 2009

Phosphorus binders and survival on hemodialysis.  20:388-396. 2009

C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts.  20:197-204. 2009

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.  20:1103-1112. 2009

Toll-like receptor 9 affects severity of IgA nephropathy.  19:2384-2395. 2008

Donor ethnicity influences outcomes following deceased-donor kidney transplantation in black recipients.  19:2011-2019. 2008

Oscillating cortical thick ascending limb cells at the juxtaglomerular apparatus.  19:1940-1946. 2008

Heme oxygenase-1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis.  19:1681-1691. 2008

Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis.  19:1629-1633. 2008

Resolved: Fistulas are preferred to grafts as initial vascular access for dialysis. Con..  19:1632-1633. 2008

Impact of activated vitamin D and race on survival among hemodialysis patients.  19:1379-1388. 2008

Urinary proteomics in diabetes and CKD.  19:1283-1290. 2008

Standard versus high-dose CVVHDF for ICU-related acute renal failure.  19:1233-1238. 2008

Systolic dysfunction portends increased mortality among those waiting for renal transplant.  19:1190-1196. 2008

Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.  19:1008-1014. 2008

Efficacy and safety of renal tubule cell therapy for acute renal failure.  19:1034-1040. 2008

Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function..  19:455-468. 2008

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.  19:615-623. 2008

Obesity impacts access to kidney transplantation.  19:349-355. 2008

Age affects outcomes in chronic kidney disease.  18:2758-2765. 2007

Antiproteinuric therapy and fabry nephropathy: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-β.  18:2609-2617. 2007

Improving outcomes from acute kidney injury.  18:1992-1994. 2007

Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula.  18:1936-1941. 2007

Opening Pandora's box in the tight junction.  18:1624-1625. 2007

Enzyme replacement therapy and fabry kidney disease: Quo vadis?.  18:1368-1370. 2007

Role of primary cilia in the pathogenesis of polycystic kidney disease.  18:1381-1388. 2007

Advances in urinary proteome analysis and biomarker discovery.  18:1057-1071. 2007

Immunoglobulin light chains generate hydrogen peroxide.  18:1239-1245. 2007

Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study.  18:1344-1352. 2007

EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells.  18:131-142. 2007

Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.  18:143-154. 2007

Baseline predictors of renal disease progression in the African American study of hypertension and kidney disease.  17:2928-2936. 2006

Uric acid: An old dog with new tricks?.  17:1767-1768. 2006

Racial differences in the prevalence of chronic kidney disease among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study.  17:1710-1715. 2006

Serum uric acid: A risk factor and a target for treatment?.  17. 2006

Mortality risk stratification in chronic kidney disease: One size for all ages?.  17:846-853. 2006

Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I).  17:3204-3212. 2006

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.  16:2205-2215. 2005

Kinesin family member 12 is a candidate polycystic kidney disease modifier in the cpk mouse.  16:905-916. 2005

Association of achieved dialysis dose with mortality in the hemodialysis study: An example of "dose-targeting bias".  16:3371-3380. 2005

IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease.  16:3651-3660. 2005

Renal sodium handling: The role of the epithelial sodium channel.  16:3151-3153. 2005

Time-dependent associations between iron and mortality in hemodialysis patients.  16:3070-3080. 2005

Towards a definition and classification of acute kidney injury.  16:3149-3150. 2005

Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage.  15:1244-1253. 2004

Glycosylation and Size of IgA1 Are Essential for Interaction with Mesangial Transferrin Receptor in IgA Nephropathy.  15:622-634. 2004

Comparison of Arteriovenous Grafts in the Thigh and Upper Extremities in Hemodialysis Patients.  14:2942-2947. 2003

Neuronal nitric oxide synthase: Its role and regulation in macula densa cells.  14:2475-2483. 2003

Racial differences in early-onset renal disease among young adults: The coronary artery risk development in young adults (CARDIA) study.  14:2352-2357. 2003

Impact of dialysis dose and membrane on infection-related hospitalization and death: Results of the HEMO study.  14:1863-1870. 2003

Gene delivery in renal tubular epithelial cells using recombinant adeno-associated viral vectors.  14:947-958. 2003

The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia.  13:2508-2516. 2002

Connective tissue growth factor (CTGF) N fragment: A marker for progressive diabetic nephropathy..  13:249A-249A. 2002

Role of P1P(2) and PIP3 in the regulation of ENaC by purinergic and corticoid receptors..  13:277A-277A. 2002

Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT1 receptors.  13:1131-1135. 2002

Purinergic receptor signaling at the basolateral membrane of macula densa cells.  13:1145-1151. 2002

Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome.  13:699-707. 2002

Hepatocyte growth factor alters renal epithelial cell susceptibility to uropathogenic Escherichia coli.  12:2543-2553. 2001

Manganese superoxide dismutase attenuates cisplatin-induced renal injury: Importance of superoxide.  12:2683-2690. 2001

Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus.  12:1630-1639. 2001

Impact of sodium and ultrafiltration profiling on hemodialysis-related symptoms.  12:151-156. 2001

Coronary heart disease in chronic renal insufficiency: Some management considerations.  11:1948-1956. 2000

Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation..  11 Suppl 15:S1-86. 2000

Renal response to tissue injury: Lessons from heme oxygenase-1 gene ablation and expression.  11:965-973. 2000

Glycolate metabolism by Hep G2 cells.  10. 1999

Increased nitric oxide synthase-3 expression in kidneys of deoxycorticosterone acetate-salt hypertensive rats.  10:2283-2289. 1999

P2 purinoceptor saturation by adenosine triphosphate impairs renal autoregulation in dogs.  10:492-498. 1999

Angiotensin II stimulates macula densa basolateral sodium/hydrogen exchange via type 1 angiotensin II receptors.  10. 1999

Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats.  10. 1999

Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.  10. 1999

Linoleyl hydroperoxide transcriptionally upregulates heme oxygenase-1 gene expression in human renal epithelial and aortic endothelial cells.  9:1990-1997. 1998

Losartan, an Angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.  9:1104-1108. 1998

Epidemiology of IgA nephropathy in central and eastern Kentucky for the period 1975 through 1994.  9:853-858. 1998

Differential activation of the Na:Ca exchanger by PMA in mesangial cells from salt sensitive hypertensive rats..  8:A1422-A1422. 1997

ET(A) receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat.  8:1054-1060. 1997

Agonist-induced calcium regulation in freshly isolated renal microvascular smooth muscle cells.  8:569-579. 1997

Temporal Induction of Clusterin in Cisplatin Nephrotoxicity.  8:302-305. 1997

Dominantly transmitted glomerulocystic kidney disease A distinct genetic entity.  8:77-84. 1997

Evaluation of pathologic criteria for acute renal allograft rejection: Reproducibility, sensitivity, and clinical correlation.  8:1930-1941. 1997

Expression of the amiloride-sensitive sodium channel β subunit gene in human B lymphocytes.  8:126-129. 1997

Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective study.  7:831-835. 1996

Polymorphism in the beta subunit and Na⁺ transport.  7:2490-2494. 1996

Homocysteine and folate concentrations in blood from patients treated with hemodialysis.  7:2414-2418. 1996

The evaluation of living renal transplant donors: Clinical practice guidelines.  7:2288-2313. 1996

The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians..  7:2288-2313. 1996

Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: Current concepts and management.  6:1160-1169. 1995

The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians..  6:1-34. 1995

Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients.  5:1426-1433. 1995

Effects of dietary salt on angiotensin peptides in kidney.  6:1209-1215. 1995

Hyperkalemia in end-stage renal disease: Mechanisms and management.  6:1134-1142. 1995

The evaluation of renal transplant candidates: Clinical practice guidelines.  6:1-34. 1995

Translumbar inferior vena cava catheter for long-term hemodialysis.  5:2094-2097. 1995

Gene expression of epithelial glucose transporters: The role of diabetes mellitus.  5. 1994

Gene expression of epithelial glucose transporters: the role of diabetes mellitus..  5:s29. 1994

Gene expression of epithelial glucose transporters: the role of diabetes mellitus..  5:S29-S36. 1994

Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients.  3:1570-1574. 1993

The kidney in sarcoidosis.  3:1555-1562. 1993

Effects of insulin and glucose on renal phosphate reabsorption: Interactions with dietary phosphate.  2:1593-1600. 1992

Cardiovascular complications in renal failure.  2:1053-1062. 1991

Influence of adenosine receptor blockade on renal function and renal autoregulation.  2:991-999. 1991

Renal sodium and water handling in hypothyroid patients: The role of renal insufficiency.  1:205-210. 1990